Brief: New Study Validates Guardant Reveal Blood Test’s Effectiveness in Monitoring Chemotherapy Response
06/11/2025 13:45
Nov 6 (Reuters) - Guardant Health Inc GH.O: NEW STUDY VALIDATES GUARDANT REVEAL BLOOD TEST’S EFFECTIVENESS IN MONITORING CHEMOTHERAPY RESPONSE GUARDANT HEALTH: PATIENTS WHO EXPERIENCED OVER 98% REDUCTION IN TUMOR SIGNAL SAW MOST SIGNIFICANT BENEFITS GUARDANT HEALTH: RISE IN TUMOR SIGNAL IDENTIFIED DISEASE PROGRESSION UP TO 18 MONTHS EARLIER WITH MEDIAN LEAD TIME OF 2.3 MONTHS Source text: ID:nBw95n5f3a Further company coverage: GH.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Guardant Health
See all newsBrief: Guardant Health Announces Approval In Europe Of Guardant360® Cdx
Grail's cancer blood test nears landmark FDA approval, but insurance coverage looms
US Health Secretary Kennedy Jr. adds eight new members to key health committee (updated)
Brief: US FDA Grants Accelerated Approval To Etcamah For Advanced Breast Cancer With ESR1 Mutation
Brief: Guardant Health To Appeal Federal District Court Judgment